Ramesh K. Ramanathan

Author

Translational Genomics Research Institute

Also Known As

Bang, Yung-Jue, Edwards, Robert P., Findlay, Brian P., Fuchs, Charles S., Mitchel, Edith P., R K Ramanathan, R Ramanathan, R. K. Ramanathan, R. Ramanathan, R.K. Ramanathan

469

Publications

30.9K

Citations

H-Index

136

Concepts

All Affiliations

Translational Genomics Research Institute UPMC Hillman Cancer Center University of Pittsburgh Mayo Clinic in Arizona The University of Texas MD Anderson Cancer Center

About

Ramesh K. Ramanathan is an author at Translational Genomics Research Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	93	5.9K
2	Health Sciences	11	11	367
3	Engineering	7	7	768
4	Public Health	1	1	17
5	Social Sciences	1	1	13

Ramesh K. Ramanathan

188

Publications

29K

Citations

H-Index

Page 1

	Year	Citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, New England Journal of Medicine	2013	6.5K
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Journal of Clinical Oncology	2003	2.3K
Outcomes After Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity Philip R. Schauer, Sayeed Ikramuddin, William Gourash, Annals of Surgery	2000	1.3K
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07 J. Philip Kuebler, H. Samuel Wieand, Michael J. O’Connell, Journal of Clinical Oncology	2007	1K
Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Journal of Clinical Oncology	2011	1K
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial Patrick J. Loehrer, Yang Feng, Higinia R. Cárdenes, Journal of Clinical Oncology	2011	817
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Journal of Clinical Oncology Surgical OncologyPathologyPhase Ii StudyFgfr2 FusionsOncology	2017	700
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial Mace L. Rothenberg, Amit M. Oza, Robert Bigelow, Journal of Clinical Oncology	2003	642
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study Howard S. Höchster, Lowell L. Hart, Ramesh K. Ramanathan, Journal of Clinical Oncology	2008	620
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor William D. Tap, Zev A. Wainberg, Stephen P. Anthony, New England Journal of Medicine	2015	571

Page 1